Autolus Therapeutics (AUTL) Depreciation & Amortization (CF) (2018 - 2025)

Autolus Therapeutics (AUTL) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $2.1 million the latest figure, recorded in Q4 2025.

• Quarterly Depreciation & Amortization (CF) rose 11.85% year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.3 million (up 9.82% YoY) and the FY2025 annual result came in at $8.3 million, up 9.82% from the prior year.
• Depreciation & Amortization (CF) grew to $2.1 million in Q4 2025 per AUTL's latest filing, from $2.1 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for AUTL reached as high as $2.4 million in Q3 2021 and fell as low as $1.4 million in Q3 2023.
• A 5-year average of $1.9 million and a median of $1.9 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) soared 77.11% — and 2022, when it retreated 27.0%.
• Year by year, Depreciation & Amortization (CF) stood at $2.1 million in 2021, then fell by 21.63% to $1.6 million in 2022, then rose by 7.64% to $1.8 million in 2023, then gained by 7.89% to $1.9 million in 2024, then rose by 11.85% to $2.1 million in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.1 million, $2.1 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.